0000000000017945

AUTHOR

Ivano Arioli

showing 5 related works from this author

Abstract 2141: Stromal SPARC deficiency skews prostate cancer toward neuroendocrine differentiation

2018

Abstract Tumor progression is a multifaceted process in which, complex interactions between tumor and different types of stromal cells and extracellular matrix components, actively contribute to its phenotypic heterogeneity. Among extracellular matrix proteins, secreted protein acidic and rich in cysteine (SPARC) has been deeply studied since conflicting reports have described its expression to be either increased or decreased in different cancer settings, also depending on whether it is produced by the neoplasm or by the neighboring stroma. Nevertheless, the different contribution of tumor- or stromal-derived SPARC in prostate tumor microenvironment has not been addressed at least for tumo…

Cancer ResearchTumor microenvironmentStromal cellCancerBiologymedicine.diseaseNeuroendocrine differentiationProstate cancerOncologyTumor progressionmedicineCancer researchAdenocarcinomaTrampCancer Research
researchProduct

Imatinib spares cKit-expressing prostate neuroendocrine tumors, whereas kills seminal vesicle epithelial-stromal tumors by targeting PDGFR-β

2017

Abstract Prostate cancer is a leading cause of cancer-related death in males worldwide. Indeed, advanced and metastatic disease characterized by androgen resistance and often associated with neuroendocrine (NE) differentiation remains incurable. Using the spontaneous prostate cancer TRAMP model, we have shown that mast cells (MCs) support in vivo the growth of prostate adenocarcinoma, whereas their genetic or pharmacologic targeting favors prostate NE cancer arousal. Aiming at simultaneously targeting prostate NE tumor cells and MCs, both expressing the cKit tyrosine kinase receptor, we have tested the therapeutic effect of imatinib in TRAMP mice. Imatinib-treated TRAMP mice experience a pa…

0301 basic medicineMaleCancer ResearchReceptor tyrosine kinaseAntineoplastic AgentProstate cancerMice0302 clinical medicineProstatebiologySeminal VesiclesImmunohistochemistryGene Expression Regulation NeoplasticNeuroendocrine TumorsProto-Oncogene Proteins c-kitmedicine.anatomical_structureOncology030220 oncology & carcinogenesisImatinib MesylateFemaleNeuroendocrine Tumormedicine.drugTrampHumanSignal TransductionPCA3medicine.medical_specialtyStromal cellXenograft Model Antitumor AssayProtein Kinase InhibitorAntineoplastic AgentsMice TransgenicReceptor Platelet-Derived Growth Factor beta03 medical and health sciencesInternal medicineSeminal VesiclemedicineAnimalsHumansProtein Kinase InhibitorsAnimalProstatic NeoplasmsImatinibBiomarkermedicine.diseaseXenograft Model Antitumor AssaysDisease Models Animal030104 developmental biologyEndocrinologyImatinib mesylateProstatic Neoplasmbiology.proteinCancer researchBiomarkers
researchProduct

Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers

2015

// Giorgio Mauri 1 , Elena Jachetti 1 , Barbara Comuzzi 1 , Matteo Dugo 2 , Ivano Arioli 1 , Silvia Miotti 1 , Sabina Sangaletti 1 , Emma Di Carlo 3, 4 , Claudio Tripodo 5 , Mario P. Colombo 1 1 Molecular Immunology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, 20133, Milano, Italy 2 Functional Genomics and Bioinformatics, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, 20133, Milano, Italy 3 Department of Medicine and Science of Aging, Section of Anatomic Pathology and Molecular Medicine, “G. d’Annunzio” University, 66100, Chieti, Italy 4 Ce.S.I. Aging Research Center, “G…

0301 basic medicineMalePathologyFluorescent Antibody Techniquemedicine.disease_causeImmunoenzyme TechniquesProstate cancerMice0302 clinical medicineOsteopontinProstate cancerbiologyReverse Transcriptase Polymerase Chain ReactionExtracellular matrixNeuroendocrine TumorsCell Transformation NeoplasticNeuroendocrineOncology030220 oncology & carcinogenesisDisease ProgressionAdenocarcinomaTrampResearch Papermedicine.medical_specialtyBlotting WesternMice TransgenicAdenocarcinomaSettore MED/08 - Anatomia PatologicaReal-Time Polymerase Chain Reaction03 medical and health sciencesstomatognathic systemmedicineAnimalsHumansExtracellular matrix; Neuroendocrine; Osteopontin; Prostate cancer; OncologyRNA Messengerbusiness.industryGene Expression ProfilingCancerProstatic Neoplasmsmedicine.diseaseMolecular medicineMice Inbred C57BLDisease Models Animal030104 developmental biologyTumor progressionbiology.proteinOsteopontinCarcinogenesisbusinessGene Deletion
researchProduct

Ultrasound-guided intra-tumor injection of combined immunotherapy cures mice from orthotopic prostate cancer.

2013

Intra-tumor injection of immunotherapeutic agents is often the most effective, likely because of concomitant modification of tumor microenvironment. We tested an immunotherapeutic regimen consisting of CpG oligonucleotides and of adenovirus-mediated gene delivery of CCL16 chemokine directly into orthotopically implanted prostate tumors by ultrasound-guided injection, followed by systemic administration of an anti-IL-10R antibody. This combination treatment induced rapid stromal rearrangement, characterized by massive leukocyte infiltration and large areas of necrosis, a scenario that eventually led to complete tumor rejection and systemic immunity in 75 % of the treated mice. In vivo T lymp…

MaleCancer ResearchPathologymedicine.medical_specialtyStromal cellmedicine.medical_treatmentImmunologyFluorescent Antibody TechniqueGene deliveryCD8-Positive T-LymphocytesInjections Intralesionalprostate cancer;immunotherapyAdenoviridaeImmunoenzyme TechniquesProstate cancerMiceTumor Cells CulturedImmunology and AllergyMedicineAnimalsHumansCell ProliferationUltrasonographyTumor microenvironmentbusiness.industryAntibodies MonoclonalProstatic NeoplasmsImmunotherapyT lymphocyteGenetic Therapyprostate cancermedicine.diseaseCombined Modality TherapyInterleukin-10Mice Inbred C57BLOncologyOligodeoxyribonucleotidesChemokines CCSystemic administrationImmunotherapybusinessCD8Cancer immunology, immunotherapy : CII
researchProduct

SPARC oppositely regulates inflammation and fibrosis in bleomycin-induced lung damage.

2011

Fibrosis results from inflammatory tissue damage and impaired regeneration. In the context of bleomycin-induced pulmonary fibrosis, we demonstrated that the matricellular protein termed secreted protein acidic and rich in cysteine (SPARC) distinctly regulates inflammation and collagen deposition, depending on its cellular origin. Reciprocal Sparc(-/-) and wild-type (WT) bone marrow chimeras revealed that SPARC expression in host fibroblasts is required and sufficient to induce collagen fibrosis in a proper inflammatory environment. Accordingly, Sparc(-/-) >WT chimeras showed exacerbated inflammation and fibrosis due to the inability of Sparc(-/-) macrophages to down-regulate tumor necrosis …

Pathologymedicine.medical_specialtyAnimals; Bleomycin; Bone Marrow Cells; Chimera; Collagen; Down-Regulation; Fibroblasts; Leukocytes; Macrophages; Mice; Mice Inbred BALB C; Osteonectin; Pneumonia; Pulmonary Fibrosis; Transforming Growth Factor beta; Tumor Necrosis Factor-alphaPulmonary FibrosisDown-RegulationInflammationBone Marrow CellsBiologyPathology and Forensic MedicineMiceFibrosisTumor necrosis factor productionTransforming Growth Factor betaPulmonary fibrosismedicineLeukocytesAnimalsOsteonectinInbred BALB CChimeraTumor Necrosis Factor-alphaMacrophagesMatricellular proteinRegular ArticleSPARCTransforming growth factor betaPneumoniaFibroblastsBLEOMYCINmedicine.diseaseSPARC; BLEOMYCIN; LUNG DAMAGELUNG DAMAGECancer researchbiology.proteinTumor necrosis factor alphaCollagenmedicine.symptomOsteonectin
researchProduct